Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Alaunos Therapeutics (TCRT) over the last 14 years, with Q2 2025 value amounting to $31000.0.

  • Alaunos Therapeutics' Gains from Investment Securities changed N/A to $31000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $31000.0, marking a year-over-year increase of 54285.71%. This contributed to the annual value of -$7000.0 for FY2023, which is 9465.65% up from last year.
  • Alaunos Therapeutics' Gains from Investment Securities amounted to $31000.0 in Q2 2025.
  • In the past 5 years, Alaunos Therapeutics' Gains from Investment Securities ranged from a high of $307000.0 in Q4 2021 and a low of -$559000.0 during Q1 2021
  • For the 4-year period, Alaunos Therapeutics' Gains from Investment Securities averaged around -$30800.0, with its median value being -$3500.0 (2022).
  • Examining YoY changes over the last 5 years, Alaunos Therapeutics' Gains from Investment Securities showed a top increase of 3080000.0% in 2021 and a maximum decrease of 85000.0% in 2021.
  • Over the past 4 years, Alaunos Therapeutics' Gains from Investment Securities (Quarter) stood at $307000.0 in 2021, then plummeted by 141.04% to -$126000.0 in 2022, then skyrocketed by 103.97% to $5000.0 in 2023, then surged by 520.0% to $31000.0 in 2025.
  • Its Gains from Investment Securities stands at $31000.0 for Q2 2025, versus $5000.0 for Q4 2023 and -$2000.0 for Q3 2023.